John B. Porter1*, Maria Domenica Cappellini, MD2, Kevin H.M. Kuo, MD, MSc, FRCPC3,4, Maria Dimopoulou5*, Marta Reverte6*, Loyse Felber Medlin6*, Shweta Sharma7*, Kefeng Wang8*, Jennie Zhang8* and Ali T. Taher, MD, FRCP9
1University College London, University College London Hospitals, London, United Kingdom
2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, SC Medicina ad Indirizzo Metabolico, Milan, Italy
3Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, ON, Canada
4Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
5Thalassemia Unit Centre of Expertise in Hemoglobinopathies, Laiko General Hospital of Athens, Athens, Greece
6Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
7Bristol Myers Squibb, New Delhi, India
8Bristol Myers Squibb, Princeton, NJ
9Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon